• ScreenPro (SCRN) has completed its acquisition of Concierge Medical Consultants from Datametrex AI (DM)
  • Concierge Medical is an arm’s length private medical concierge services provider
  • The company paid a purchase price of C$1,800,000 in common shares
  • It views the acquisition as a strategic component of its post-pandemic business plan
  • ScreenPro Security is a medical technology company that offers proprietary testing methods and medical alerting software
  • ScreenPro (SCRN) is unchanged trading at $0.02 per share

ScreenPro (SCRN) has completed its acquisition of Concierge Medical Consultants from Datametrex AI (DM).

Concierge Medical is an arm’s length private medical concierge services provider incorporated under the laws of British Columbia. It’s comprised of a small group of board-certified practicing emergency physicians and was founded by Dr. Jibran Sharif, MD, CCFP EM, RDMS.

The company issued 36,000,000 common shares priced at C$0.05 per share for an aggregate purchase price of $1,800,000.

Lena Kozovski, CEO of ScreenPro, stated,

“We are pleased to complete the acquisition of Concierge Medical. Dr. Sharif and I have worked together for the last year on the pandemic and COVID-19 testings, and I look forward to moving Concierge Medical to the next level. Consumers view concierge services as a viable model for future medical care needs and the completion of this acquisition is a pivotal part of our post-pandemic business plan.”

Concierge Medical has become ScreenPro’s wholly-owned operating subsidiary. Sharif and Kozovski now make up Concierge Medical’s Board of Directors, with Sharif remaining as President and assuming the role of ScreenPro’s Chief Medical Officer.

ScreenPro Security is a medical technology company that offers proprietary testing methods and medical alerting software.

ScreenPro (SCRN) is unchanged trading at $0.02 per share as of 9:30 am ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.